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We have taken the business analysis to evaluate US
market potential of new technology for preventive and
personalized therapy (PT) of human diseases – Method
for screening drug preparations (Method) [1] and it
impact on the public health. Six sexually transmitted
diseases (HCV, HBV, HPV, HSV, HIV and genital
chlamidiosis), influenza, other acute respiratory dis-
eases (ARD) and cancer [2] were used for the analysis.
PT can allow to save up to $17.5 – 19.25 billion for
Medicare/Medicaid for US hepatitis C market. The
cost of the treatment of one patient with melanoma
stage II - III can decrease 3-fold (saved $3,950 per
patient per year) while the efficacy have to increase
2 – 3-fold. At cancer forms with no effective and safe
adjuvant therapy PT can decrease the rate of metastatic
stage which requires high-cost cytostatic therapy. PT
with antiretrovirals and cytostatics can allow reduction
of high expense of hospital stay for the patients with
AIDS and metastatic cancer due to higher efficacy. PT
will decrease the rate of non-effective treatment and
number of relapses of HPV-infection, genital herpes and
urogenital chlamidyosis as well as the number of new
cases due to less spreading via sexual contacts. Preven-
tive PT of HPV-infection with unfavorable HPV types
will lead to less number of cases with cervical neoplasia.
Preventive PT in risk group of 1% cases of influenza
(950,000 cases) will give the ability for the insurance
companies to save money for the treatment of 2.8 –
3.4 mln episodes of influenza and ARD. At the same
time the number of restricted-activity days will decrease
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Table 1. US estimated market potential of the Method for Screening Drug Preparations
Diseases Treatment Annual Income/ ($ mln) Treatment market/5 Years ($ mln) Prevention market ($ mln)
1. Hepatitis C 125 – 300 625 – 1,500
2. HPV infection 125 – 250 625 – 1,250 900
3. AIDS/HIV 125 – 210 625 – 1,050
4. Urogenital chlamydiosis 35 175
5. Genital herpes 25 125 3,000
6. Hepatitis B 20 100
STD (subtotal) 455 – 840 2,275 – 4,200 3,900
7. Influenza & ARD 450 (5 years)
8. Cancer 300 1,500 ???
Total 755 – 1,140 3,775 – 5,700 4,350
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for 10 – 12 mln, bed days – for 5 – 7 mln and work-loss
days due to flu and other ARD – for 2 – 2.5 mln.
The Market potential data of Method are summarized
in the table below.
Other perspective directions of PT using proposed
Method: atherosclerosis, diabetes, endometriosis, chronic
fatigue syndrome; CMV-, EBV-, HelicobacterPylori infec-
tions, sepsis and tuberculosis.
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